578
Views
28
CrossRef citations to date
0
Altmetric
Review Article

Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery

, , , , , , , & show all
Pages 430-447 | Received 03 May 2018, Accepted 06 Aug 2018, Published online: 29 Sep 2018

References

  • Abada PB, Larson CA, Manorek G, Adams P, Howell SB. 2012. Sec61 beta controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Mol Pharmacol. 82:510–520.
  • Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS. 1996. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res. 56:5435–5442.
  • Abu-Gosh SE, Kolvazon N, Tirosh B, Ringel I, Yavin E. 2009. Multiple triphenylphosphonium cations shuttle a hydrophilic peptide into mitochondria. Mol Pharm. 6:1138–1144.
  • Alam K, Pahwa S, Wang XY, Zhang PY, Ding K, Abuznait AH, Li L, Yue W. 2016. Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 transport function by lysosomotropic drug chloroquine: implication in OATP-mediated drug-drug interactions. Mol Pharm. 13:839–851.
  • Altan N, Chen Y, Schindler M, Simon SM. 1998. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med. 187:1583–1598.
  • Altan N, Chen Y, Schindler M, Simon SM. 1999. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci USA. 96:4432–4437.
  • Antonenkov VD, Hiltunen JK. 2012. Transfer of metabolites across the peroxisomal membrane. Biochim Biophys Acta. 1822:1374–1386.
  • Azzolini C, Fiorani M, Cerioni L, Guidarelli A, Cantoni O. 2013. Sodium-dependent transport of ascorbic acid in U937 cell mitochondria. IUBMB Life. 65:149–153.
  • Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM. 1995. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol. 68:226–239.
  • Bao LL, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. 2012. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 180:2490–2503.
  • Barot M, Gokulgandhi MR, Pal D, Mitra AK. 2013. Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells-novel strategies for intracellular drug targeting. Exp Eye Res. 106:47–54.
  • Barrand MA, Rhodes T, Center MS, Twentyman PR. 1993. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer. 29A:408–415.
  • Benhamou RI, Bibi M, Berman J, Fridman M. 2018. Localizing antifungal drugs to the correct organelle can markedly enhance their efficacy. Angew Chem Int Ed. 57:6230–6235.
  • Benton CR, Campbell SE, Tonouchi M, Hatta H, Bonen A. 2004. Monocarboxylate transporters in subsarcolemmal and intermyofibrillar mitochondria. Biochem Biophys Res Co. 323:249–253.
  • Bhatia P, Bernier M, Sanghvi M, Moaddel R, Schwarting R, Ramamoorthy A, Wainer IW. 2012. Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells. Xenobiotica. 42:748–755.
  • Bossuyt X, Blanckaert N. 1997. Carrier-mediated transport of uridine diphosphoglucuronic acid across the endoplasmic reticulum membrane is a prerequisite for UDP-glucuronosyltransferase activity in rat liver. Biochem J. 323:645–648.
  • Boya P, Kroemer G. 2008. Lysosomal membrane permeabilization in cell death. Oncogene. 27:6434–6451.
  • Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD. 1995. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 55:5342–5347.
  • Bridges HR, Jones AJY, Pollak MN, Hirst J. 2014. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 462:475–487.
  • Brooks GA, Brown MA, Butz CE, Sicurello JP, Dubouchaud H. 1999. Cardiac and skeletal muscle mitochondria have a monocarboxylate transporter MCT1. J Appl Physiol. 87:1713–1718.
  • Cabrita MA, Hobman TC, Hogue DL, King KM, Cass CE. 1999. Mouse transporter protein, a membrane protein that regulates cellular multidrug resistance, is localized to lysosomes. Cancer Res. 59:4890–4897.
  • Cai BL, Miao Y, Liu Y, Xu XF, Guan SM, Wu JZ, Liu YP. 2013. Nuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: a human mucoepidermoid carcinoma cells model and Spearman's Rank Correlation Analysis. PLoS One. 8:e69611.
  • Cai BL, Xu XF, Fu SM, Shen LL, Zhang J, Guan SM, Wu JZ. 2011. Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma. Oral Oncol. 47:1134–1140.
  • Canton I, Battaglia G. 2012. Endocytosis at the nanoscale. Chem Soc Rev. 41:2718–2739.
  • Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG. 2009. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematol-Hematol J. 94:1528–1536.
  • Chen VY, Posada MM, Zhao LL, Rosania GR. 2007. Rapid doxorubicin efflux from the nucleus of drug-resistant cancer cells following extracellular drug clearance. Pharm Res. 24:2156–2167.
  • Cheng SH, Lam W, Lee ASK, Fung KP, Wu RSS, Fong WF. 2000. Low-level doxorubicin resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP expression and altered subcellular drug distribution. Toxicol Appl Pharm. 164:134–142.
  • Chung H, Yoon YH, Hwang JJ, Cho KS, Koh JY, Kim JG. 2009. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol Appl Pharmacol. 235:163–170.
  • Cocheme HM, Kelso GF, James AM, Ross MF, Trnka J, Mahendiran T, Asin-Cayuela J, Blaikie FH, Manas ARB, Porteous CM, et al. 2007. Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion. 7:S94–S102.
  • Coley HM, Amos WB, Twentyman PR, Workman P. 1993. Examination by laser-scanning confocal fluorescence imaging microscopy of the subcellular-localization of anthracyclines in parent and multidrug-resistant cell-lines. Br J Cancer. 67:1316–1323.
  • Colombo F, Trombetta E, Cetrangolo P, Maggioni M, Razini P, De Santis F, Torrente Y, Prati D, Torresani E, Porretti L. 2014. Giant lysosomes as a chemotherapy resistance mechanism in hepatocellular carcinoma cells. PLoS One. 9:e114787.
  • Csala M, Marcolongo P, Lizak B, Senesi S, Margittai E, Fulceri R, Magyar JE, Benedetti A, Banhegyi G. 2007. Transport and transporters in the endoplasmic reticulum. Biochim Biophys Acta. 1768:1325–1341.
  • Csala M, Margittai E, Banhegyi G. 2010. Redox control of endoplasmic reticulum function. Antioxid Redox Signal. 13:77–108.
  • Dahabieh MS, Ha Z, Di Pietro E, Nichol JN, Bolt AM, Goncalves C, Dupere-Richer D, Pettersson F, Mann KK, Braverman NE, et al. 2017. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. Cell Death Differ. 24:1912–1924.
  • Dartier J, Lemaitre E, Chourpa I, Goupille C, Servais S, Chevalier S, Maheo K, Dumas JF. 2017. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells. BBA-Gen Subjects. 1861:1075–1084.
  • de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. 1974. Commentary. Lysosomotropic agents. Biochem Pharmacol. 23:2495–2531.
  • Denamur S, Tyteca D, Marchand-Brynaert J, Van Bambeke F, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. 2011. Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. Free Radic Biol Med. 51:1656–1665.
  • Donmez Y, Gunduz U. 2011. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Biomed Pharmacother. 65:85–89.
  • Duvvuri M, Krise JP. 2005. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol Pharm. 2:440–448.
  • Dzamitika S, Salerno M, Pereira-Maia E, Le Moyec L, Garnier-Suillerot A. 2006. Preferential energy- and potential-dependent accumulation of cisplatin-gutathione complexes in human cancer cell lines (GLC4 and k562): a likely role of mitochondria. J Bioenerg Biomembr. 38:11–21.
  • Elbaz Y, Schuldiner M. 2011. Staying in touch: the molecular era of organelle contact sites. Trends Biochem Sci. 36:616–623.
  • Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. 2005. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci USA. 102:192–197.
  • Fei YJ, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA. 1994. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature. 368:563–566.
  • Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. 2016. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Update. 26:1–9. DOI:10.1016/j.drup.2016.03.001
  • Fransen M, Nordgren M, Wang B, Apanasets O. 2012. Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. Biochim Biophys Acta. 1822:1363–1373.
  • Freeze HH, Ng BG. 2011. Golgi glycosylation and human inherited diseases. Cold Spring Harb Perspect Biol. 3:a005371.
  • Fu D, Arias IM. 2012. Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol. 44:461–464.
  • Fu D, Bebawy M, Kable EPW, Roufogalis BD. 2004. Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. Int J Cancer. 109:174–181.
  • Fu D, Roufogalis BD. 2007. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. Am J Physiol-Cell Ph. 292:C1543–C1C52.
  • Fulda S, Galluzzi L, Kroemer G. 2010. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 9:447–464.
  • Funk RS, Krise JP. 2012. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol Pharm. 9:1384–1395.
  • Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, Akiyama S. 2008. Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem. 15:3268–3278.
  • Galluzzi L, Bravo-San Pedro JM, Kroemer G. 2014. Organelle-specific initiation of cell death. Nat Cell Biol. 16:728–736.
  • Gasser PJ, Hurley MM, Chan J, Pickel VM. 2017. Organic cation transporter 3 (OCT3) is localized to intracellular and surface membranes in select glial and neuronal cells within the basolateral amygdaloid complex of both rats and mice. Brain Struct Funct. 222:1913–1928.
  • Gillingham AK, Munro S. 2016. Finding the Golgi: Golgin coiled-coil proteins show the way. Trends Cell Biol. 26:399–408.
  • Gong YP, Duvvuri M, Krise JP. 2003. Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem. 278:50234–50239.
  • Gong YP, Wang YT, Chen FY, Han JY, Miao JM, Shao NX, Fang ZW, Yang RO. 2000. Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leuk Res. 24:769–774.
  • Gorlich D, Kutay U. 1999. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol. 15:607–660.
  • Govindarajan R, Leung GPH, Zhou M, Tse C-M, Wang J, Unadkat JD. 2009. Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol-Gastr L. 296:G910–GG22.
  • Habicht KL, Frazier C, Singh N, Shimmo R, Wainer IW, Moaddel R. 2013. The synthesis and characterization of a nuclear membrane affinity chromatography column for the study of human breast cancer resistant protein (BCRP) using nuclear membranes obtained from the LN-229 cells. J Pharm Biomed. 72:159–162.
  • Han M, Lv Q, Tang XJ, Hu YL, Xu DH, Li FZ, Liang WQ, Gao JQ. 2012. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release. 163:136–144.
  • Han M, Vakili MR, Soleymani Abyaneh H, Molavi O, Lai R, Lavasanifar A. 2014. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells. Mol Pharm. 11:2640–2649.
  • Han X, Kemper RA, Jepson GW. 2005. Subcellular distribution and protein binding of perfluorooctanoic acid in rat liver and kidney. Drug Chem Toxicol. 28:197–209.
  • Hashimoto T, Hussien R, Brooks GA. 2006. Colocalization of MCT1, CD147, and LDH in mitochondrial inner membrane of L6 muscle cells: evidence of a mitochondrial lactate oxidation complex. Am J Physiol-Endoc M. 290:E1237–E1E44.
  • He L, Vasiliou K, Nebert DW. 2009. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics. 3:195–206.
  • Heikkinen AT, Monkkonen J, Korjamo T. 2009. Kinetics of cellular retention during Caco-2 permeation experiments: role of lysosomal sequestration and impact on permeability estimates. J Pharmacol Exp Ther. 328:882–892.
  • Heritage D, Wonderlin WF. 2001. Translocon pores in the endoplasmic reticulum are permeable to a neutral, polar molecule. J Biol Chem. 276:22655–22662.
  • Herrmann JM, Riemer J. 2010. The intermembrane space of mitochondria. Antioxid Redox Signal. 13:1341–1358.
  • Hoepfner D, Schildknegt D, Braakman I, Philippsen P, Tabak HF. 2005. Contribution of the endoplasmic reticulum to peroxisome formation. Cell. 122:85–95.
  • Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. 2008. Mitochondria-penetrating peptides. Chem Biol. 15:375–382.
  • Hu YP, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. 2000. rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol. 60:1897–1905.
  • Huo XK, Wang C, Yu ZL, Peng YL, Wang SM, Feng SN, Zhang SJ, Tian XG, Sun CP, Liu KX, et al. 2017. Human transporters, PEPT1/2, facilitate melatonin transportation into mitochondria of cancer cells: an implication of the therapeutic potential. J Pineal Res. 62:e12390.
  • Ifergan I, Jansen G, Assaraf YG. 2005. Cytoplasmic confinement of breast cancer resistance protein (BCRP/ABCG2) as a novel mechanism of adaptation to short-term folate deprivation. Mol Pharmacol. 67:1349–1359.
  • Jean SR, Ahmed M, Lei EK, Wisnovsky SP, Kelley SO. 2016. Peptide-mediated delivery of chemical probes and therapeutics to mitochondria. Acc Chem Res. 49:1893–1902.
  • Jungsuwadee P, Nithipongvanitch R, Chen YM, Oberley TD, Butterfield DA, Clair DKS, Vore M. 2009. Mrp1 localization and function in cardiac mitochondria after doxorubicin. Mol Pharmacol. 75:1117–1126.
  • Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell M. 2017. Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms. Interface Focus. 7:20160109.
  • Karttunen JT, Lehner PJ, Gupta SS, Hewitt EW, Cresswell P. 2001. Distinct functions and cooperative interaction of the subunits of the transporter associated with antigen processing (TAP). *Proc Natl Acad Sci USA. 98:7431–7436.
  • Katayama K, Kapoor K, Ohnuma S, Patel A, Swaim W, Ambudkar IS, Ambudkar SV. 2015. Revealing the fate of cell surface human P-glycoprotein (ABCB1): the lysosomal degradation pathway. Biochim Biophys Acta. 1853:2361–2370.
  • Kaufmann AM, Toro-Ramos AJ, Krise JP. 2008. Assessment of Golgi apparatus versus plasma membrane-localized multi-drug resistance-associated protein 1. Mol Pharm. 5:787–794.
  • Kc S, Carcamo JM, Golde DW. 2005. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J. 19:1657–1667.
  • Ke CJ, Chiang WL, Liao ZX, Chen HL, Lai PS, Sun JS, Sung HW. 2013. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance. Biomaterials. 34:1–10. DOI:10.1016/j.biomaterials.2012.09.023
  • Kikutani Y, Kobayashi M, Konishi T, Sasaki S, Narumi K, Furugen A, Takahashi N, Iseki K. 2016. Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity. J Pharm Sci-Us. 105:1544–1549.
  • Kim HW, Chan QL, Afton SE, Caruso JA, Lai B, Weintraub NL, Qin ZY. 2012. Human macrophage ATP7A is localized in the trans-Golgi apparatus, controls intracellular copper levels, and mediates macrophage responses to dermal wounds. Inflammation. 35:167–175.
  • Kobayashi T, Sleeman JE, Coughtrie MW, Burchell B. 2006. Molecular and functional characterization of microsomal UDP-glucuronic acid uptake by members of the nucleotide sugar transporter (NST) family. Biochem J. 400:281–289.
  • Kobuchi H, Moriya K, Ogino T, Fujita H, Inoue K, Shuin T, Yasuda T, Utsumi K, Utsumi T. 2012. Mitochondrial localization of ABC transporter ABCG2 and its function in 5-aminolevulinic acid-mediated protoporphyrin IX accumulation. PLoS One. 7:e50082.
  • Koepsell H. 2013. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 34:413–435.
  • Kosic M, Arsikin-Csordas K, Paunovic V, Firestone RA, Ristic B, Mircic A, Petricevic S, Bosnjak M, Zogovic N, Mandic M, et al. 2016. Synergistic anticancer action of lysosomal membrane permeabilization and glycolysis inhibition. J Biol Chem. 291:22936–22948.
  • Krishnamachary N, Center MS. 1993. The Mrp gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53:3658–3661.
  • Lai YR, Tse CM, Unadkat JD. 2004. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem. 279:4490–4497.
  • Lamhonwah AM, Ackerley CA, Tilups A, Edwards VD, Wanders RJ, Tein I. 2005. OCTN3 is a mammalian peroxisomal membrane carnitine transporter. Biochem Biophys Res Co. 338:1966–1972.
  • Lamhonwah AM, Tein I. 2006. Novel localization of OCTN1, an organic cation/carnitine transporter, to mammalian mitochondria. Biochem Biophys Res Co. 345:1315–1325.
  • Lash LH. 2012. Mitochondrial glutathione in toxicology and disease of the kidneys. Toxicol Res. 1:39–46.
  • Lee JH, Lee JE, Kim Y, Lee H, Jun HJ, Lee SJ. 2014. Multidrug and toxic compound extrusion protein-1 (MATE1/SLC47A1) is a novel flavonoid transporter. J Agric Food Chem. 62:9690–9698.
  • Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al. 2010. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 16:214–218.
  • Liang SC, Yang CY, Tseng JY, Wang HL, Tung CY, Liu HW, Chen CY, Yeh YC, Chou TY, Yang MH, et al. 2015. ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells. Neoplasia. 17:265–278.
  • Ling X, He Y, Zhang G, Zhou Y, Yan B. 2012. Increased P-glycoprotein expression in mitochondria is related to acquired multidrug resistance in human hepatoma cells depleted of mitochondrial DNA. Int J Oncol. 40:109–118.
  • Ling XL, Zhou YA, Li SW, Yan B, Wen L. 2010. Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells. Int J Biol Sci. 6:773–783.
  • Liu B, Czajka A, Malik AN, Hussain K, Jones PM, Persaud SJ. 2015. Equilibrative nucleoside transporter 3 depletion in beta-cells impairs mitochondrial function and promotes apoptosis: relationship to pigmented hypertrichotic dermatosis with insulin-dependent diabetes. BBA-Mol Basis Dis. 1852:2086–2095.
  • Logan R, Kong AC, Krise JP. 2014. Time-dependent effects of hydrophobic amine-containing drugs on lysosome structure and biogenesis in cultured human fibroblasts. J Pharm Sci. 103:3287–3296.
  • Lyamzaev KG, Pustovidko AV, Simonyan RA, Rokitskaya TI, Domnina LV, Ivanova OY, Severina II, Sumbatyan NV, Korshunova GA, Tashlitsky VN, et al. 2011. Novel mitochondria-targeted antioxidants: plastoquinone conjugated with cationic plant alkaloids berberine and palmatine. Pharm Res. 28:2883–2895.
  • Mao QC, Unadkat JD. 2015. Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in drug transport-an update. AAPS J. 17:65–82.
  • Marquardt D, Center MS. 1992. Drug transport mechanisms in Hl-60 cells isolated for resistance to adriamycin – evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res. 52:3157–3163.
  • Merlin JL, Bour-Dill C, Marchal S, Ramacci C, Poullain MG, Giroux B. 2000. Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in golgi vesicles. Cytometry. 41:62–72.
  • Meschini S, Marra M, Calcabrini A, Monti E, Gariboldi M, Dolfini E, Arancia G. 2002. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol In Vitro. 16:389–398.
  • Molinari A, Cianfriglia M, Meschini S, Calcabrini A, Arancia G. 1994. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int J Cancer. 59:789–795.
  • Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu CH, Nagaraja AS, Gharpure KM, Kang Y, et al. 2013. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 123:2119–2130.
  • Moriyama Y, Manabe T, Yoshimori T, Tashiro Y, Futai M. 1994. Atp-dependent uptake of anti-neoplastic agents by acidic organelles. J Biochem. 115:213–218.
  • Munoz-Montesino C, Roa FJ, Pena E, Gonzalez M, Sotomayor K, Inostroza E, Munoz CA, Gonzalez I, Maldonado M, Soliz C, et al. 2014. Mitochondrial ascorbic acid transport is mediated by a low-affinity form of the sodium-coupled ascorbic acid transporter-2. Free Radic Biol Med. 70:241–254.
  • Munteanu E, Verdier M, Grandjean-Forestier F, Stenger C, Jayat-Vignoles C, Huet S, Robert J, Ratinaud MH. 2006. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol. 71:1162–1174.
  • Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y. 2011. A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro. 25:715–723.
  • Neve EP, Ingelman-Sundberg M. 2008. Intracellular transport and localization of microsomal cytochrome P450. Anal Bioanal Chem. 392:1075–1084.
  • Nies AT, Damme K, Kruck S, Schaeffeler E, Schwab M. 2016. Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Arch Toxicol. 90:1555–1584.
  • Nunnari J, Suomalainen A. 2012. Mitochondria: in sickness and in health. Cell. 148:1145–1159.
  • Ohno N, Tani A, Uozumi K, Hanada S, Furukawa T, Akiba S, Sumizawa T, Utsunomiya A, Arima T, Akiyama S. 2001. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood. 98:1160–1165.
  • Owen MR, Doran E, Halestrap AP. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 348:607–614.
  • Pascual-Ahuir A, Manzanares-Estreder S, Proft M. 2017. Pro- and antioxidant functions of the peroxisome–mitochondria connection and its impact on aging and disease. Oxid Med Cell Longev. 2017:9860841.
  • Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D’Souza GGM. 2010. Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res. 20:244–249.
  • Pathak RK, Marrache S, Harn DA, Dhar S. 2014. Mito-DCA: a mitochondria targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate. ACS Chem Biol. 9:1178–1187.
  • Porteous CM, Logan A, Evans C, Ledgerwood EC, Menon DK, Aigbirhio F, Smith RAJ, Murphy MP. 2010. Rapid uptake of lipophilic triphenylphosphonium cations by mitochondria in vivo following intravenous injection: implications for mitochondria-specific therapies and probes. BBA-Gen Subjects. 1800:1009–1017.
  • Rocco A, Compare D, Liguori E, Cianflone A, Pirozzi G, Tirino V, Bertoni A, Santoriello M, Garbi C, D'Armiento M, et al. 2012. MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Lab Invest. 92:1407–1418.
  • Ross MF, Kelso GF, Blaikie FH, James AM, Cocheme HM, Filipovska A, Da Ros T, Hurd TR, Smith RA, Murphy MP. 2005. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochem Mosc. 70:222–230.
  • Roth M, Obaidat A, Hagenbuch B. 2012. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 165:1260–1287.
  • Roundhill E, Turnbull D, Burchill S. 2016. Localization of MRP-1 to the outer mitochondrial membrane by the chaperone protein HSP90 beta. FASEB J. 30:1712–1723.
  • Roundhill EA, Burchill SA. 2012. Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria. Br J Cancer. 106:1224–1233.
  • Rowland A, Mackenzie PI, Miners JO. 2015. Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition. Drug Metab Dispos. 43:147–153.
  • Rowland A, Miners JO, Mackenzie PI. 2013. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 45:1121–1132.
  • Seebacher N, Lane DJR, Richardson DR, Jansson PJ. 2016. Turning the gun on cancer: utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. Free Radic Biol Med. 96:432–445.
  • Seebacher NA, Lane DJR, Jansson PJ, Richardson DR. 2016. Glucose modulation induces lysosome formation and increases lysosomotropic drug sequestration via the P-glycoprotein drug transporter. J Biol Chem. 291:3796–3820.
  • Seebacher NA, Richardson DR, Jansson PJ. 2016. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death Dis. 7:e2510.
  • Serafim TL, Oliveira PJ, Sardao VA, Perkins E, Parke D, Holy J. 2008. Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemother Pharmacol. 61:1007–1018.
  • Settembre C, Fraldi A, Medina DL, Ballabio A. 2013. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol. 14:283–296.
  • Shen Y, Chu Y, Yang Y, Wang ZH. 2012. Mitochondrial localization of P-glycoprotein in the human breast cancer cell line MCF-7/ADM and its functional characterization. Oncol Rep. 27:1535–1540.
  • Shieh MJ, Hsu CY, Huang LY, Chen HY, Huang FH, Lai PS. 2011. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release. 152:418–425.
  • Shitara Y, Nakamichi N, Norioka M, Shima H, Kato Y, Horie T. 2013. Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. Toxicol Sci. 132:32–42.
  • Solazzo M, Fantappie O, D'Amico M, Sassoli C, Tani A, Cipriani G, Bogani C, Formigli L, Mazzanti R. 2009. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. Cancer Res. 69:7235–7242.
  • Solazzo M, Fantappie O, Lasagna N, Sassoli C, Nosi D, Mazzanti R. 2006. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res. 312:4070–4078.
  • Szaflarski W, Sujka-Kordowska P, Januchowski R, Wojtowicz K, Andrzejewska M, Nowicki M, Zabel M. 2013. Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line. Biomed Pharmacother. 67:497–502.
  • Takanaga H, Frommer WB. 2010. Facilitative plasma membrane transporters function during ER transit. FASEB J. 24:2849–2858.
  • Tamai I, China K, Sai Y, Kobayashi D, Nezu J, Kawahara E, Tsuji A. 2001. Na(+)-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim Biophys Acta. 1512:273–284.
  • Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A. 1997. The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol. 49:796–801.
  • Valenca I, Pertega-Gomes N, Vizcaino JR, Henrique RM, Lopes C, Baltazar F, Ribeiro D. 2015. Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. J Cell Mol Med. 19:723–733.
  • Vasiliou V, Vasiliou K, Nebert DW. 2009. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 3:281–290.
  • Voeltz GK, Rolls MM, Rapoport TA. 2002. Structural organization of the endoplasmic reticulum. EMBO Rep. 3:944–950.
  • Wenzel U, Schoberl K, Lohner K, Daniel H. 2005. Activation of mitochondrial lactate uptake by flavone induces apoptosis in human colon cancer cells. J Cell Physiol. 202:379–390.
  • Weylandt KH, Nebrig M, Jansen-Rosseck N, Amey JS, Carmena D, Wiedenmann B, Higgins CF, Sardini A. 2007. ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment. Mol Cancer Ther. 6:979–986.
  • Wlcek K, Hofstetter L, Stieger B. 2014. Transport of estradiol-17β-glucuronide, estrone-3-sulfate and taurocholate across the endoplasmic reticulum membrane: evidence for different transport systems. Biochem Pharmacol. 88:106–118.
  • Woldemichael GM, Turbyville TJ, Linehan WM, McMahon JB. 2011. Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells. Cancer Res. 71:134–142.
  • Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. 2013. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem. 288:31761–31771.
  • Yamauchi Y, Iwamoto N, Rogers MA, Abe-Dohmae S, Fujimoto T, Chang CC, Ishigami M, Kishimoto T, Kobayashi T, Ueda K, et al. 2015. Deficiency in the lipid exporter ABCA1 impairs retrograde sterol movement and disrupts sterol sensing at the endoplasmic reticulum. J Biol Chem. 290:23464–23477.
  • Yang HB, Li X, Cai YC, Wang Q, Li WH, Liu GX, Tang Y. 2017. In silico prediction of chemical subcellular localization via multi-classification methods. Med Chem Commun. 8:1225–1234.
  • Yang IW, Chou CC, Yung BY. 1996. Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Naunyn Schmiedebergs Arch Pharmacol. 354:102–108.
  • Yu PC, Yu HJ, Guo CY, Cui ZR, Chen XZ, Yin Q, Zhang PC, Yang XL, Cui HG, Li YP. 2015. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles. Acta Biomater. 14:115–124.
  • Zheng N, Tsai HN, Zhang X, Rosania GR. 2011a. The subcellular distribution of small molecules: from pharmacokinetics to synthetic biology. Mol Pharm. 8:1619–1628.
  • Zheng N, Tsai HN, Zhang X, Shedden K, Rosania GR. 2011b. The subcellular distribution of small molecules: a meta-analysis. Mol Pharm. 8:1611–1618.
  • Zhitomirsky B, Assaraf YG. 2015. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 6:1143–1156.
  • Zhitomirsky B, Assaraf YG. 2017. Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis. Oncotarget. 8:45117–45132.
  • Zhou FF, Xing D, Wu BY, Wu SN, Ou ZM, Chen WR. 2010. New insights of transmembranal mechanism and subcellular localization of noncovalently modified single-walled carbon nanotubes. Nano Lett. 10:1677–1681.
  • Zhou W, Wang XY, Hu M, Zhu CC, Guo ZJ. 2014. A mitochondrion-targeting copper complex exhibits potent cytotoxicity against cisplatin-resistant tumor cells through multiple mechanisms of action. Chem Sci. 5:2761–2770.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.